These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 31040893)

  • 1. Identification of genomic features associated with immunotherapy response in gastrointestinal cancers.
    He Y; Liu ZX; Jiang ZH; Wang XS
    World J Gastrointest Oncol; 2019 Apr; 11(4):270-280. PubMed ID: 31040893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
    Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Li L; Li M; Jiang Z; Wang X
    Cells; 2019 Jul; 8(7):. PubMed ID: 31277418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and emerging immunotherapeutic approaches for biliary tract cancers.
    Yuan ZG; Zeng TM; Tao CJ
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rare case of sporadic mismatch repair deficient pancreatic ductal adenocarcinoma that responded to ipilimumab and nivolumab combination treatment: case report.
    Han MY; Borazanci E
    J Gastrointest Oncol; 2023 Feb; 14(1):458-462. PubMed ID: 36915432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA mismatch repair in cancer.
    Baretti M; Le DT
    Pharmacol Ther; 2018 Sep; 189():45-62. PubMed ID: 29669262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
    Li L; Li M; Wang X
    DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of immunotherapy in gastrointestinal malignancies.
    Lorenzen S; Lordick F; Loosen SH; Tacke F; Trautwein C; Roderburg C; Ettrich TJ; Perkhofer L; Reinacher-Schick A; Stein A
    Z Gastroenterol; 2020 Jun; 58(6):542-555. PubMed ID: 32018315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients.
    Duffy MJ; Crown J
    Clin Chem; 2019 Oct; 65(10):1228-1238. PubMed ID: 31315901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy in Castration-resistant Prostate Cancer.
    Klümper N; Grünwald V; Hartmann A; Hölzel M; Eckstein M
    Eur Urol; 2024 May; ():. PubMed ID: 38744632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers.
    Lu Z; Peng Z; Liu C; Wang Z; Wang Y; Jiao X; Li J; Shen L
    Innovation (Camb); 2020 Aug; 1(2):100041. PubMed ID: 34557714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].
    Cohen R; Pudlarz T; Garcia-Larnicol ML; Vernerey D; Dray X; Clavel L; Jary M; Piessen G; Zaanan A; Aparicio T; Louvet C; Tournigand C; Chibaudel B; Tougeron D; Guimbaud R; Benouna J; Adenis A; Sokol H; Borg C; Duval A; Svrcek M; André T
    Bull Cancer; 2020 Apr; 107(4):438-446. PubMed ID: 32057467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy.
    Kim ST; Klempner SJ; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim KM; Lee J
    Oncotarget; 2017 Sep; 8(44):77415-77423. PubMed ID: 29100397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating Colorectal Cancer with Immunotherapy: Implications for Single versus Combination Therapy.
    Karki S; Umar S; Kasi A
    Curr Colorectal Cancer Rep; 2020 Oct; 16(5):107-117. PubMed ID: 33132786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The spliceosome pathway activity correlates with reduced anti-tumor immunity and immunotherapy response, and unfavorable clinical outcomes in pan-cancer.
    Chen Z; Chen C; Li L; Zhang T; Wang X
    Comput Struct Biotechnol J; 2021; 19():5428-5442. PubMed ID: 34667536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
    Bilgin B; Sendur MA; Bülent Akıncı M; Şener Dede D; Yalçın B
    Curr Med Res Opin; 2017 Apr; 33(4):749-759. PubMed ID: 28055269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.